- New Dexcom product with 15-day wear, a cash-pay option and a
tailored software experience for people who don’t use insulin is
expected to launch in the U.S. in 2024
- Access and availability of Dexcom CGM is expanding globally,
with Dexcom G7 now available in 14 countries and the recent launch
of Dexcom ONE in Argentina marking the company’s first entrance
into Latin America
- Private payers in the U.S. are following Medicare’s lead faster
than expected; 60% of commercial insurers now cover Dexcom CGM for
people with Type 2 diabetes on basal insulin1
- In addition, new projections estimate 3-4 million people in the
US have a history of problematic hypoglycemia,* and many of them
are now covered for Dexcom CGM through Medicare†
- This weekend, ADA conference symposia, posters and
presentations will reinforce the safety, industry-leading
accuracy,2 connectivity2 and affordability3 of Dexcom CGM
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time
continuous glucose monitoring (CGM) for people living with
diabetes, announced today its strategy to bring Dexcom glucose
sensing technology to millions more people around the globe and new
Dexcom CGM research featured at the 83rd Scientific Sessions of the
American Diabetes Association being held June 23-26 in San
Diego.
During Dexcom’s Investor Day event held earlier today the
company revealed plans to bring a new product to market in the U.S.
in 2024, designed specifically for people who don’t use insulin
(which is about 70% of Americans living with diabetes).* The
product, which will feature a 15-day sensor and include a cash-pay
option, will also offer a new software experience tailored for
people not on insulin.
“Dexcom is building a world in which our care for users includes
not only helping them in the management of chronic conditions, but
the potential to help prevent the onset and progression of disease
through better metabolic health,” said Kevin Sayer, chairman,
president and CEO of Dexcom. “There is so much that people who
don’t use insulin can learn by receiving continuous glucose data
and seeing first-hand how diet, exercise, sleep, stress and other
factors affect their overall health.”
Additionally, new projections following the expansion of
Medicare CGM coverage in April show that 3-4 million people in the
U.S. have a history of problematic hypoglycemia,* and many of them
are now covered for CGM through Medicare’s expanded policy.† In
addition, commercial insurers in the U.S. are following Medicare’s
lead to cover CGM for people living with Type 2 diabetes on basal
insulin faster than expected, with 60% commercial coverage for this
population already in place.1 This important group of people with
Type 2 diabetes can now more easily access Dexcom G7, the most
accurate CGM system,2 which 96% of users say is easy to use.2
“Thanks to our efforts to continually expand coverage, millions
more people now have access to Dexcom CGM and our industry-leading
features such as connectivity to multiple automated insulin
delivery systems, the Urgent Low Soon alert, and
Follow—Dexcom-pioneered features that help keep users safe by
helping them avoid extreme glucose fluctuations and stay within
target range,” said Teri Lawver, executive vice president and chief
commercial officer at Dexcom.
As diabetes becomes increasingly prevalent, it’s more important
than ever for people with all types of diabetes around the world to
have better access to the #1 recommended CGM brand.4,5 Dexcom G7
has now launched in 14 countries across five continents, and the
recent launch of Dexcom ONE in Argentina marks Dexcom’s first
entrance into Latin America.
This weekend during the 83rd Scientific Sessions of ADA, Dexcom
will be prominently featured in key symposia, posters and
presentations that demonstrate the positive impact of Dexcom CGM on
health outcomes and cost savings. Highlights of these exhibitions
include:
Pioneering industry leading CGM technology
Dexcom G7 is the most accurate,2 simple to use2 CGM system
available, with the best coverage.3
- 141-LB/142-LB: Cost-Effectiveness of rtCGM vs. isCGM from a US
Payer & Canadian Perspective with T2D on MDI Therapy; Saturday,
June 24, 11:30 am–12:30 pm PDT; Hamza Alshannaq
- 151-LB: Expansion of Medicaid Coverage of CGM Reduces Health
Disparity; Saturday, June 24, 11:30 am–12:30 pm PDT; Lily Chao
- Dexcom Product Theatre: Introducing G7: Simplicity, Solutions,
and Successes for Your Patients and Your Practice; Saturday, June
24, 3:00–3:45 pm PDT; Nicholas Argento and Thomas Martens
- 358-OR: Better Adherence to rtCGM vs. isCGM Among People with
T2D on MDI Therapy; Sunday, June 25, 5:00–5:15 pm PDT; Poorva
Nemlekar
Driving unparalleled connectivity
Dexcom CGM works with more automated insulin delivery systems
than any other CGM brand globally. With more than 30 published
studies6 and 10 years of industry partnerships, Dexcom is the clear
choice for AID systems.
- 57-OR: Real World Glycemic Outcomes of >5900 Adults with T1D
Using Omnipod 5 AID; Friday, June 23, 3:15–3:30 pm PDT; Rayhan
Lal
- 59-OR: Glycemic Control with Extended Use of AID in Children
Ages 2-6 with T1D; Friday, June 23, 2:15– 2:30 pm PDT; Paul
Wadwa
- 108-LB: RCT of AID in Pregnant Women with T1D; Saturday, June
24, 11:30 am–12:30 pm PDT; Helen Murphy
- 943-P: Improved Glycemic Outcomes After 1 Year among Level 2
Members; Saturday, June 24, 11:30 am–12:30 pm PDT; Sam Bacon
- Insulet Product Theatre: One Year of Omnipod 5: Real World
Learnings for Optimized Care; Sunday, June 25, 10:15–11:00 am PDT;
Trang Ly, Jennifer Sherr and Anne Peters
Expanding access to those who can benefit
With expanded coverage, Dexcom is a premier CGM for people with
Type 2 diabetes using insulin and at high-risk for
hypoglycemia.
- Dexcom Corporate Symposium: rtCGM: Going Beyond the Obvious;
Saturday, June 24, 6:00–7:45 am PDT; Grazia Aleppo, Athena
Philis-Tsimikas, Celeste Durnwald, Thomas Grace and Jane Jeffrie
Seley
- 63-LB: rtCGM Is Associated with Improved Clinical and
Psychosocial Health in People with T2D on Basal Insulin; Saturday,
June 24, 11:30 am–12:30 pm PDT; Maggie Crawford
- 677-P: Exploring the Impact of CGM on Perceived Control on
Non-Intensive Insulin Treated T2D; Saturday, June 24, 11:30
am–12:30 pm PDT; Maggie Crawford
- 991-P: Reduction in Diabetes-Related Hospitalizations and
Medical Costs after rtCGM Initiation in Patients with T2D on MDI
Therapy; Sunday, June 25, 11:30 am–12:30 pm PDT; Katia Hannah
Charting a new frontier of sensing technology
Dexcom is defining the future of CGM—developing a new product
for people who don’t use insulin.
- 1-OR: Burden of Hypoglycemia in Medicare Advantage
Beneficiaries with T2D Not on Insulin; Friday, June 23. 12:45–1:00
pm PDT; Katia Hannah
- Dexcom Corporate Symposium: rtCGM: Going Beyond the Obvious;
Saturday, June 24, 6:00–7:45 am PDT; Grazia Aleppo, Athena
Philis-Tsimikas, Celeste Durnwald, Thomas Grace and Jane Jeffrie
Seley
- 941-P: Improved Glycemic Control with rtCGM in Adults with T2D
Not Treated with Insulin; Saturday, June 24, 11:30 am–12:30 pm PDT;
Jennifer Layne
For more information about the 83rd Scientific Sessions of the
ADA and to register to virtually attend the conference, visit
professional.diabetes.org/scientific-sessions. To watch a recording
of Dexcom’s 2023 Investor Day presentation, visit
investors.dexcom.com.
About Dexcom, Inc.
Dexcom, Inc. empowers people to take real-time control of health
through innovative continuous glucose monitoring systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
on Dexcom, visit Dexcom.com.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act and Section 21E of
the Securities Exchange Act of 1934 that involve risks and
uncertainties, including, without limitation, the expected features
and timing of launch of a new product in the U.S. in 2024 and
Dexcom’s participation in the 83rd Scientific Sessions of the ADA.
Statements containing words such as “could,” “believe,” “expect,”
“intend,” “will,” or similar expressions constitute forward-looking
statements. For information about potential factors that could
affect Dexcom’s business and financial results, please review the
“Risk Factors” described in Dexcom’s Quarterly Report on Form 10-Q
for the three months ended March 31, 2023, filed with the
Securities and Exchange Commission (SEC) on April 27, 2023, and in
Dexcom’s other filings with the SEC. Except as may be required by
law, Dexcom does not intend, and undertakes no duty, to update this
information to reflect future events or circumstances.
Disclosure Information
Dexcom uses and intends to continue to use its Investor
Relations website (investors.dexcom.com) as a means of disclosing
material information to the public and for complying with its
disclosure obligations under Regulation FD. Accordingly, investors
should monitor Dexcom’s Investor Relations website, in addition to
following the company’s press releases, SEC filings, public
conference calls, presentations, and webcasts.
_______________________________________ *Estimates based on CDC
National Diabetes Statistics Report, where available, and internal
market research. †Medicare covers Dexcom CGM for patients who meet
the Medicare coverage criteria. For a list of Medicare coverage
criteria, visit the Centers for Medicare and Medicaid Services
website.
1 MMIT, May 2023. 2 Dexcom, data on file, 2022. 3 Managed
Markets Insights & Technology, LLC. MMIT Analytics, June 2022.
4 d&A US Q1 2021 Diabetes Connections Patient Panel
Report.2021;69-72. 5 Seagrove HCP Survey Q1 2021. 2021;65. 6
Peacock S, et al. Diabetes Ther. 2023;14(5):839-855.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230623025076/en/
Media Contact James McIntosh
619-884-2118 james.mcintosh@dexcom.com Investor Contact Sean Christensen 858-203-6657
sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
DexCom (NASDAQ:DXCM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024